Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Beard

Showing results (531-540 of 576) with videos related to

Pageof 58
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2014
Incidence and determinants of 1-month mortality after cancer-directed surgeryB A Mahal, G Inverso, A A Aizer, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Plos One|September 18, 2024
A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) ReleaseDeborah J Thompson, Daniel Wells, Saskia Selzam, et al.
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care ActB A Mahal, A A Aizer, D R Ziehr, et al.
Pageof 58

Showing results (531-540 of 576) with videos related to

Sort By:
Pageof 58
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2014
Incidence and determinants of 1-month mortality after cancer-directed surgeryB A Mahal, G Inverso, A A Aizer, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Plos One|September 18, 2024
A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) ReleaseDeborah J Thompson, Daniel Wells, Saskia Selzam, et al.
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care ActB A Mahal, A A Aizer, D R Ziehr, et al.
Pageof 58